市场快照
| Study Period: | 2016-2027 |
| Base Year: | 2021 |
| Fastest Growing Market: | Middle East and Africa |
| Largest Market: | North America |
| CAGR: | 0 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
- 胰高血糖素样肽-1 (GLP-1) 激动剂市场预计在预测期内将出现相当大的增长。这一增长主要归因于 GLP-1 效率的提高。
- 预计成熟国家和新兴国家糖尿病患病率的增加将推动市场。多年来糖尿病人口的增加是由于个体层面因素的整体影响，例如人口中位年龄的增加和健康因素，包括人们肥胖率和不活动水平的增加。
- 此外，在日本、意大利、德国和法国等老年人口比例较高的国家，出生率降低以及预期寿命延长预计将推动市场增长。
报告范围
市场按药物（艾塞那肽、利拉鲁肽、度拉鲁肽、利西拉肽）、品牌（Byetta、Bydureon、Victoza、Trulicity、Lyxumia）和地理位置进行细分。
| By Drug | ||||
| ||||
| ||||
| ||||
|
| Geography | ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
|
主要市场趋势
全球糖尿病高患病率的持续趋势
- GLP-1的销售额与全球糖尿病高发趋势成正比。
- 例如，一些重要国家的 2 型糖尿病比例如下：中国 22.8%，阿曼 17.2%，马来西亚 12.9%，依此类推。
- 据估计，全球约有 83.9 亿美元用于糖尿病。预计这些国家中产阶级家庭数量的增长以及人均收入的增加将总体上提高消费能力，从而有助于在预测期内（2019-2024 年）推动市场。
- 除此之外，一些关键因素，如先进的医疗基础设施、技术进步和熟练医疗专业人员的可用性，可能会在该市场的整体增长中发挥范式转变作用。
To understand key trends, Download Sample Report
北美将在收入方面主导市场
- 北美占整个 GLP-1 市场的 77%，预计在预测期内增长率为 6.53%。
- 在中东和非洲，预计 GLP-1 市场在预测期内将出现高速增长，复合年增长率为 25.08%。
- 在亚太地区，根据国际糖尿病联合会的数据，日本和澳大利亚的人均支出最高，超过 3,000 美元。然而，中国和印度的糖尿病患病率最高。
To understand geography trends, Download Sample Report
竞争格局
- 全球 GLP-1 市场得到巩固，四大制造商在所有地区都有业务。
- 目前，市场上没有 GLP-1 的通用版本，因为这些药物受专利保护。然而，梯瓦（Teva）确认了仿制药 Victoza 并宣布已向美国食品药品监督管理局（FDA）提交了一份简化的新药申请（ANDA），寻求批准在美国销售 NovoNordisk 的 Victoza®（利拉鲁肽）注射液的仿制药。状态。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Drivers
-
4.3 Restraints
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Bargaining Power of Suppliers
-
4.4.2 Bargaining Power of Consumers
-
4.4.3 Threat of New Entrants
-
4.4.4 Threat of Substitute Products and Services
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Drug
-
5.1.1 Exenatide
-
5.1.1.1 Byetta (Value and Volume 2012-2024)
-
5.1.1.2 Bydureon (Value and Volume 2012-2024)
-
-
5.1.2 Liraglutide
-
5.1.2.1 Victoza (Value and Volume 2012-2024)
-
-
5.1.3 Lixisenatide
-
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
-
-
5.1.4 Dulaglutide
-
5.1.4.1 Trulicity (Value and Volume 2012-2024)
-
-
-
5.2 Geography
-
5.2.1 North America
-
5.2.1.1 US (Value and Volume 2012-2024)
-
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.1.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.1.2 Canada (Value and Volume 2012-2024)
-
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.1.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
-
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.1.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
-
5.2.2 Europe
-
5.2.2.1 Germany (Value and Volume 2012-2024)
-
5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.2.2 Spain (Value and Volume 2012-2024)
-
5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.2.3 Italy (Value and Volume 2012-2024)
-
5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.2.4 France (Value and Volume 2012-2024)
-
5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.4.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.2.5 UK (Value and Volume 2012-2024)
-
5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.5.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.2.6 Russia (Value and Volume 2012-2024)
-
5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.6.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
-
5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.2.7.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
-
5.2.3 Asia-Pacific
-
5.2.3.1 Japan (Value and Volume 2012-2024)
-
5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.2 China (Value and Volume 2012-2024)
-
5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.3 Australia (Value and Volume 2012-2024)
-
5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.4 India (Value and Volume 2012-2024)
-
5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.4.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.5 South Korea (Value and Volume 2012-2024)
-
5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.5.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.6 Malaysia (Value and Volume 2012-2024)
-
5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.6.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.7 Indonesia (Value and Volume 2012-2024)
-
5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.7.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.8 Thailand (Value and Volume 2012-2024)
-
5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.8.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.9 Philippines (Value and Volume 2012-2024)
-
5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.9.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
-
5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.3.10.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
-
5.2.4 Latin America
-
5.2.4.1 Brazil (Value and Volume 2012-2024)
-
5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.4.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.4.2 Mexico (Value and Volume 2012-2024)
-
5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.4.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
-
5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.4.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
-
5.2.5 Middle East & Africa
-
5.2.5.1 South Africa (Value and Volume 2012-2024)
-
5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.5.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
-
5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.5.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.5.3 Oman (Value and Volume 2012-2024)
-
5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.5.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.5.4 Egypt (Value and Volume 2012-2024)
-
5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.5.4.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.5.5 Iran (Value and Volume 2012-2024)
-
5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.5.5.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
-
5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
-
5.2.5.6.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)
-
-
-
-
-
6. MARKET INDICATORS
-
6.1 Type-1 Diabetes Population (2012-2024)
-
6.2 Type-2 Diabetes Population (2012-2024)
-
-
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
-
7.1.1 NovoNordisk
-
7.1.2 Sanofi
-
7.1.3 Eli Lilly
-
7.1.4 AstraZeneca
-
-
7.2 MARKET SHARE ANALYSIS
-
7.2.1 NovoNordisk
-
7.2.2 Sanofi
-
7.2.3 Eli Lilly
-
7.2.4 AstraZeneca
-
-
-
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Glucagon-like Peptide-1 (GLP-1) Agonists Market market is studied from 2016 - 2027.
What is the growth rate of Glucagon-like Peptide-1 (GLP-1) Agonists Market?
The Glucagon-like Peptide-1 (GLP-1) Agonists Market is growing at a CAGR of 0% over the next 5 years.
Which region has highest growth rate in Glucagon-like Peptide-1 (GLP-1) Agonists Market?
Middle East and Africa is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Glucagon-like Peptide-1 (GLP-1) Agonists Market?
North America holds highest share in 2021.
Who are the key players in Glucagon-like Peptide-1 (GLP-1) Agonists Market?
Novo Nordisk, AstraZeneca, Eli Lilly and Company, Sanofi are the major companies operating in Glucagon-like Peptide-1 (GLP-1) Agonists Market.
